Health Care & Life Sciences » Biotechnology | Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,512
2,215
2,486
3,011
3,532
4,133
Cost of Goods Sold (COGS) incl. D&A
179
193
350
580
622
689
Gross Income
1,333
2,022
2,136
2,431
2,910
3,444
SG&A Expense
797
1,130
1,572
1,711
1,946
1,823
EBIT
536
892
-
720
965
1,622
Unusual Expense
40
13
145
126
359
1,350
Non Operating Income/Expense
31
12
119
68
21
17
Interest Expense
4
3
48
97
97
112
Pretax Income
526
872
498
576
548
242
Income Tax
273
215
354
177
105
165
Consolidated Net Income
253
657
144
399
443
78
Net Income
253
657
144
399
443
78
Net Income After Extraordinaries
253
657
144
399
443
78
Net Income Available to Common
253
657
144
399
443
78
EPS (Basic)
1.27
3.26
0.67
1.76
1.97
0.35
Basic Shares Outstanding
196
198
213
224
224
223
EPS (Diluted)
1.27
3.26
0.67
1.76
1.97
0.35
Diluted Shares Outstanding
200
202
216
227
225
225
EBITDA
564
939
725
1,106
1,452
2,019
Non-Operating Interest Income
3
8
8
11
19
65

About Alexion Pharmaceuticals

View Profile
Address
121 Seaport Boulevard
Boston Massachusetts 02210
United States
Employees -
Website http://www.alexion.com
Updated 07/08/2019
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.